Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.
Biomarker
durvalumab
head and neck squamous cell carcinoma
immune checkpoint inhibitor
overall survival
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
17 03 2021
17 03 2021
Historique:
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
3
8
2021
Statut:
epublish
Résumé
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline to identify potential biomarkers and to understand pathways related to clinical outcomes for durvalumab. Prior to treatment, 66 serum proteins were measured using multiplex immunoassays for 158 durvalumab-treated HNSCC patients in the phase II HAWK and CONDOR trials as a discovery dataset and 209 durvalumab-treated HNSCC patients in the phase III EAGLE trial as a validation dataset. Multivariate Cox modeling of HAWK and CONDOR datasets established that higher baseline concentrations of interleukin-6 (IL-6), C-reactive protein, S100 calcium-binding protein A12, and angiopoietin-2 (ANGPT2) were associated with shorter overall survival (OS), while higher concentrations of osteocalcin correlated with longer OS after durvalumab treatment (
Identifiants
pubmed: 33796405
doi: 10.1080/2162402X.2021.1898104
pii: 1898104
pmc: PMC7993189
doi:
Substances chimiques
Antibodies, Monoclonal
0
Biomarkers
0
durvalumab
28X28X9OKV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1898104Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Cancer Cell. 2011 Apr 12;19(4):512-26
pubmed: 21481792
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Biochem Biophys Res Commun. 2017 Apr 29;486(2):239-244
pubmed: 28254435
Ann Oncol. 2020 Jul;31(7):942-950
pubmed: 32294530
J Clin Oncol. 2020 Jan 1;38(1):63-70
pubmed: 31721643
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
Science. 2017 Dec 1;358(6367):1127-1128
pubmed: 29191891
Expert Rev Respir Med. 2020 Feb;14(2):125-136
pubmed: 31829747
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
Oral Oncol. 2019 Apr;91:47-55
pubmed: 30926062
J Proteomics. 2010 Sep 10;73(10):1790-803
pubmed: 20139037
Ann Transl Med. 2019 Jul;7(Suppl 3):S75
pubmed: 31576284
Cancer Immunol Res. 2017 Jan;5(1):17-28
pubmed: 28003187
Eur J Cancer. 2019 Jan;107:142-152
pubmed: 30576970
Mediators Inflamm. 2013;2013:434010
pubmed: 23533306
Oncoimmunology. 2013 Dec 1;2(12):e27215
pubmed: 24501692
Cancer Res. 2015 Dec 1;75(23):5084-92
pubmed: 26627641
PLoS One. 2013;8(2):e54923
pubmed: 23405099
J Cancer. 2017 Aug 2;8(13):2478-2486
pubmed: 28900485
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Transl Oncol. 2019 Feb;12(2):245-255
pubmed: 30439625
Cancer Res. 2018 Sep 1;78(17):5011-5022
pubmed: 29967259
Ther Adv Med Oncol. 2018 Apr 07;10:1758835918768238
pubmed: 29662549
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
J Transl Med. 2011 Jul 20;9:113
pubmed: 21774806
PLoS One. 2019 Mar 20;14(3):e0213934
pubmed: 30893350
Cancer Sci. 2017 Oct;108(10):1959-1966
pubmed: 28746799
Ann Oncol. 2017 Aug 1;28(8):1988-1995
pubmed: 28595336
J Immunother Cancer. 2019 Nov 27;7(1):325
pubmed: 31775882
Immunol Rev. 1995 Jun;145:91-122
pubmed: 7590832
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Hepatology. 2017 Jan;65(1):89-103
pubmed: 27770462
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581042
Br J Cancer. 2016 Feb 2;114(3):256-61
pubmed: 26794281
Clin Cancer Res. 2013 Dec 15;19(24):6730-40
pubmed: 24097868
Cancer Res. 2010 Dec 15;70(24):10150-60
pubmed: 21159637
Expert Rev Mol Diagn. 2019 Oct;19(10):895-904
pubmed: 31469965
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Laryngoscope. 2019 Nov;129(11):2506-2513
pubmed: 30637762
Ann N Y Acad Sci. 2015 Jul;1347:45-51
pubmed: 25773744
Int J Gynecol Cancer. 2020 Jan;30(1):139-143
pubmed: 31645423
Calcif Tissue Int. 2006 Jun;78(6):343-7
pubmed: 16830204
J Clin Oncol. 2009 Jul 20;27(21):3557-65
pubmed: 19546406
Eur J Cancer Clin Oncol. 1988 Jul;24(7):1211-7
pubmed: 3262063
Acta Otorhinolaryngol Ital. 2017 Dec;37(6):458-466
pubmed: 28663597
Nat Commun. 2020 Jan 30;11(1):602
pubmed: 32001684
Front Immunol. 2019 Apr 26;10:867
pubmed: 31105696